| |
|
|
|
NeuBase Therapeutics Inc.  
|
|
8.45 -0.23 (-0.03%) |
07-02 10:37 |
|
Open: |
8.82 |
Pre close: |
8.68 |
Target:
|
11.76
|
|
High: |
8.82 |
Low: |
7.97 |
Resistance:
|
10.07
11.78
|
|
Volume: |
311,703 |
Market Cap: |
195M |
Support:
|
7.31
6.08
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
8.88
 |
MACD |
MACD(12,26):
|
0.17 |
|
MA(20): |
9.29  |
Signal(12,26,9): |
0.39 |
|
MA(100): |
7.74 |
Stochastic Oscillator |
%K(14,3):
|
23.23 |
|
MA(250): |
6.51 |
%D(3): |
31.18 |
|
Average Volume(K) |
3-Month: |
41363
|
52-Week |
High:
|
11.78 |
|
10-Days: |
59967 |
Low: |
3.36 |
|
RSI |
RSI(14):
|
44.73 |
Change(%): |
122.2 |
|
Financials, Statistics and Valuation |
|
EPS |
-3.260 |
Return on Equity (ttm) |
0.0 |
Shares Out. (M) |
23.12 |
|
EPS Est. Current Year |
0.000 |
Return on Assets (ttm) |
0.0 |
Shares Float (M) |
16.08 |
|
EPS Est. Next Year |
0.000 |
PEG Ratio |
0.00 |
% Held by Insiders |
21.80 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
16.92 |
|
Forward EPS |
-3.260 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
927 |
|
Book Value (p.s.) |
0.590 |
EBITDA (p.s.) |
-1.330 |
P/E |
-2.61 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
14.42 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-6.84 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
0.00 |
P/CF |
-28.76 |
|
|
|
|
|
|
